Opinion

Video

Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

Author(s):

Jason Porter, MD

A key opinion leader examines the combination therapy of amivantamab and lazertinib in the CHRYSALIS-2 study for treatment-naïve patients or those with 2 or more prior lines of therapy, and its potential implications for non-small cell lung cancer treatment.

Video content above is prompted by the following questions:

  • Discuss the data that was presented at the ASCO 2024 on combination use amivantamab and lazertinib in the CHRYSALIS-2 study for patients who were treatment-naïve or had ≤ 2 prior lines.
  • Based on this study, how do you think amivantamab plus lazertinib compares with other current therapies used for EGFR mutations in NSCLC?
  • How might the safety data from this study impact treatment decisions and management strategies in clinical practice?
Related Videos
Ticiana Leal, MD, Emory Winship Cancer Institute
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Jason Porter, MD, an expert on lung cancer
1 KOL is featured in this program.
1 KOL is featured in this program.
Joseph Mikhael, MD, an expert on multiple myeloma
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Related Content
Joshua K. Sabari, MD, NYU Langone
August 30th 2024

Novel Mechanisms Set FDA-Approved Amivantamab-Lazertinib Combo Apart in NSCLC

Maggie L. Shaw
This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.
Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
August 27th 2024

Measuring the Magnitude of Systemic Inflammatory Response in NSCLC

Julia Bonavitacola
Measures of systemic inflammation used for the liver, including C-reactive protein-albumin ratio and modified Glasgow prognostic score, demonstrated prognostic value in non–small cell lung cancer (NSCLC).
David P. Carbone, MD, PhD, The Ohio State University
August 23rd 2024

Beyond Early Stage: Biomarker Testing's Role in Advanced Lung Cancer

Maggie L. Shaw
In part 1 of our interview with David P. Carbone, MD, PhD, The Ohio State University, he addressed why it is important to conduct biomarker testing in both lung cancer overall and non–small cell lung cancer more specifically.
FDA Approved
August 20th 2024

Lazertinib With Amivantamab Approved by FDA for Use in NSCLC

Julia Bonavitacola
Patients with non-small cell lung cancer (NSCLC) can use lazertinib in combination with amivantamab as a first-line treatment.
brain and lungs | Image Credit: magicmine-stock.adobe.com
August 15th 2024

ICIs Extend Survival in Older Patients With NSCLC, Brain Metastases

Maggie L. Shaw
This investigation was conducted among older, frail patients, a population typically underrepresented in clinical trials.
Biomarker Testing: Key to Personalized Lung Cancer Care
August 9th 2024

Biomarker Testing: Key to Personalized Lung Cancer Care

Maggie L. Shaw
David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small cell lung cancer specifically.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo